A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes

British Journal of Clinical Pharmacology

Volumn 78, Issue 1, 2014, Pages 69-77

  Baksi, Arun ^a   Kraydashenko, Oleg ^b   Zalevkaya, Alsu ^c   Stets, Roman ^b   Elliott, Peter ^d   Haddad, Jonathan ^d   Hoffmann, Ethan ^d   Vlasuk, George P ^d   Jacobson, Eric W ^d  

^a ST MARY S HOSPITAL   (United Kingdom)

^b ZAPORIZHZHIA STATE MEDICAL UNIVERSITY   (Ukraine)

^c St Petersburg City Hospital 2   (Russian Federation)

^d GLAXOSMITHKLINE   (United States)

Author keywords

glucose homeostasis; insulin; SIRT1; sirtuin; SRT2104; type 2 diabetes mellitus

Indexed keywords

ACETYLCYSTEINE; AMINOPHYLLINE; ANTIDIABETIC AGENT; CEFTRIAXONE; DEXAMETHASONE; GLUCOSE; HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; LIPID; METFORMIN; PLACEBO; SIRTUIN 1; SRT 2104; UNCLASSIFIED DRUG; ENZYME ACTIVATOR; FUSED HETEROCYCLIC RINGS; GLUCOSE BLOOD LEVEL; SIRT1 PROTEIN, HUMAN; SRT2104;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WOUND INFECTION; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG EFFECTS; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENZYME ACTIVATION; ENZYME ACTIVATORS; FEMALE; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; INSULIN; MALE; METFORMIN; MIDDLE AGED; SIRTUIN 1;

EID: 84902983036     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12327     Document Type: Article

References (15)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M,; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011; 378: 31-40.
2. Chen L, Magliano DJ, Zimmet PZ,. The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rev Endocrinol 2011; 8: 228-236.
3. Pinhas-Hamiel O, Zeitler P,. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 2005; 146: 693-700.
4. Unger J,. Current strategies for evaluating, monitoring, and treating type 2 diabetes mellitus. Am J Med 2008; 121 (Suppl. 6): S3-8.
5. Li X, Kazgan N,. Mammalian sirtuins and energy metabolism. Int J Biol Sci 2011; 7: 575-587.
6. Moynihan KA, Grimm AA, Plueger MM, Bernal-Mizrachi E, Ford E, Cras-Méneur C, Permutt MA, Imai S,. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab 2005; 2: 105-117.
7. Bordone L, Motta MC, Picard F, Robinson A, Jhala US, Apfeld J, MaDonagh T, Lemieux M, McBurney M, Szilvasi A, Easlon EJ, Lin S, Guarente L,. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol 2006; 4: e31.
8. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschöp MH,. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A 2008; 105: 9793-9798.
9. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nukes JJ, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH,. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007; 450: 712-716.
10. Pui YN, Jean EB, Jeremy SD, Chi BV, Christopher JO, Amy VL, David PC, Thomas VR, Jeffrey S, Jesse JS, Siva L, Angela T, Meghan D, Marie Y, Kristina K, Akanksha G, Vipin S, Peter JE, Jill CM, Joseph JN, Michael RJ, George PV, James LE, Robert BP,. The identification of the SIRT1 activator SRT2104 as a clinical candidate. Lett Drug Des Discov 2013; 10: 793-797.
11. Qi Y, Davis ML, Hirsch ML, Cote AM, Lainez EO, Johnson MO, Gagne DJ, Vlasuk GP, Ellis JL,. Activation of sirtuin1 (SIRT1) by the novel small molecule SRT2104 promotes body weight loss, increases exercise capacity and improves insulin sensitivity in diet-induced obese mice. Diabetes 2010; 59 (Suppl. 1): 390-PP.
12. Qi Y, Davis ML, Lainez EO, Cote AM, Johnson MO, Gagne DJ, Vlasuk GP, Ellis JL, Suri V,. SRT2104, a novel small molecule SIRT1 activator ameliorates insulin resistance and promotes glucose utilization measured under a hyperinsulinemic-euglycemic clamp by enhancing both glycolysis and carbohydrate oxidation in mice fed a high fat diet. Diabetes 2011; 60 (Suppl. 1): 1007-P.
13. Hoffmann E, Wald J, Lavu S, Roberts J, Beaumont C, Haddad J, Elliott P, Westphal C, Vlasuk GP, Jacobson EW,. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. Br J Clin Pharmacol 2013; 75: 186-196.
14. Nemoto S, Fergusson MM, Finkel T,. SIRT1 functionally interacts with metabolic regulator and transcriptional coactivator PGC-1α. J Biol Chem 2005; 280: 16456-16460.
15. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, Spiegelman BM,. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999; 98: 115-124